Marginal Zone Lymphoma: Symptoms, Causes, and Treatment Options

Marginal zone lymphoma is an uncommon type of slow-growing B-cell non-Hodgkin lymphoma. It often develops gradually and may not need treatment immediately, but care is individualized according to its subtype, location, symptoms, and overall health.

Overview: What Is Marginal Zone Lymphoma?

Marginal zone lymphoma is a type of non-Hodgkin lymphoma that begins in B lymphocytes, a kind of white blood cell involved in the immune system. In this condition, B cells grow and collect abnormally, usually in lymph nodes or tissues that contain immune cells. Most marginal zone lymphomas are considered indolent, meaning they often grow slowly and can be managed over many years.

There are three main subtypes. Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue, often called MALT lymphoma, develops outside lymph nodes, commonly in the stomach but also in organs such as the salivary glands, lungs, thyroid, skin, or tissues around the eye. Nodal marginal zone lymphoma begins primarily in lymph nodes. Splenic marginal zone lymphoma mainly affects the spleen, blood, and bone marrow.

The outlook can vary from person to person. Some localized cases can be treated successfully with local therapy, while others behave as long-term conditions requiring periodic assessment and treatment only when necessary. Although marginal zone lymphoma may occasionally transform into a faster-growing lymphoma, this is not the usual course; ongoing follow-up is important for recognizing significant changes promptly.

Symptoms and How the Condition May Present

Marginal zone lymphoma may cause no symptoms, especially when it is found at an early stage through tests performed for another reason. When symptoms occur, they depend largely on where the lymphoma is located. Painless swelling of lymph nodes in the neck, armpit, or groin can occur with nodal disease, while an enlarged spleen may cause fullness or discomfort under the left ribs and a feeling of becoming full quickly after eating.

General lymphoma symptoms can include persistent tiredness, unexplained fever, drenching night sweats, unintentional weight loss, or itching. These are sometimes called B symptoms, but they are not present in everyone with marginal zone lymphoma. They can also result from many non-cancerous conditions, so their presence does not by itself establish a diagnosis.

MALT lymphoma may produce site-specific symptoms. Stomach involvement can cause indigestion, nausea, upper abdominal discomfort, or, less commonly, bleeding. Lymphoma involving salivary glands may lead to persistent gland swelling, and disease around the eye may cause a painless lump, swelling, or changes in appearance. New, persistent, or worsening symptoms should be assessed by a qualified clinician.

Causes and Risk Factors

The exact cause of marginal zone lymphoma is not fully understood. It develops when B cells acquire genetic changes that affect how they survive and multiply. These changes are generally acquired during life rather than inherited directly from a parent. Most people with marginal zone lymphoma do not have a clear, identifiable cause.

Long-standing immune stimulation appears to play a role in some cases. For example, MALT lymphoma of the stomach is strongly associated with chronic infection by Helicobacter pylori, a bacterium that can inflame the stomach lining. Certain autoimmune conditions, including Sjögren disease and Hashimoto thyroiditis, are associated with a higher likelihood of MALT lymphoma in the salivary glands or thyroid. Some infections have also been linked to lymphoma at particular sites, although these associations vary by region and individual circumstances.

A weakened immune system, whether related to an immune disorder or immune-suppressing medicines, may increase the risk of some lymphomas. However, having a risk factor does not mean a person will develop marginal zone lymphoma, and many people diagnosed with it have no known risk factors. There is no established lifestyle change that can reliably prevent the condition.

Diagnosis and Staging

A diagnosis requires a tissue biopsy. A specialist removes all or part of an enlarged lymph node, or takes a sample from an affected organ, and a pathologist examines the cells under a microscope. Laboratory tests on the sample, such as immunohistochemistry, flow cytometry, and genetic or molecular testing when appropriate, help identify the lymphoma subtype and rule out other B-cell lymphomas.

After diagnosis, clinicians assess how much of the body is involved and whether treatment is needed. This may include a medical history, physical examination, complete blood count, liver and kidney tests, and tests for infections that could affect treatment planning. Imaging, commonly CT or PET/CT scanning, may be used to evaluate lymph nodes and organs. Bone marrow testing is sometimes recommended, particularly for splenic or nodal marginal zone lymphoma.

For suspected stomach MALT lymphoma, endoscopy with multiple biopsies is important, and testing for H. pylori is usually performed. Staging is valuable because it guides care, but stage alone does not determine the need for immediate treatment. A person with widespread but symptom-free, slow-growing lymphoma may be monitored, whereas a localized lymphoma causing symptoms may benefit from treatment.

Treatment Options and Active Monitoring

Treatment is tailored to the subtype, disease location and extent, symptoms, blood counts, pace of growth, previous treatments, and personal preferences. For people without troublesome symptoms or organ impairment, active monitoring, sometimes called watchful waiting, can be an appropriate approach. This involves scheduled appointments, examinations, and selected blood tests or imaging rather than ignoring the lymphoma. Starting treatment later does not necessarily worsen outcomes when the disease is stable and closely followed.

In stomach MALT lymphoma associated with H. pylori, antibiotic treatment to eliminate the infection may lead to lymphoma regression and is commonly the first step. Localized marginal zone lymphoma at other sites may be treated with radiation therapy. Anti-CD20 antibody treatment, most commonly rituximab, may be used alone or combined with chemotherapy when disease is more extensive, symptomatic, or affecting organs or blood counts.

Other options for selected patients can include targeted medicines, immunomodulatory treatment, or combination regimens. Surgery is not commonly used as the main lymphoma treatment, though it may be needed for diagnosis or for a specific complication. Relapsed disease can often be treated with another effective approach. A hematologist or lymphoma specialist can explain the expected benefits, possible side effects, and follow-up plan for each option.

Acibadem International’s multidisciplinary specialists and JCI-accredited hospitals diagnose and treat marginal zone lymphoma for international patients, with treatment plans based on pathology review, staging, and individual clinical needs.

Living Well During Follow-up and Treatment

People living with marginal zone lymphoma can support their general health by attending planned follow-up visits and reporting new symptoms rather than waiting until the next appointment. Keeping a brief record of fever, night sweats, weight changes, infections, unusual bruising, persistent fatigue, or enlarging lumps can make discussions with the care team more useful. Follow-up schedules differ according to subtype, treatment status, and overall health.

A balanced diet, regular movement within personal ability, adequate sleep, and avoiding tobacco can support wellbeing during monitoring or treatment. There is no specific diet, vitamin, or complementary therapy proven to cure marginal zone lymphoma. Before starting supplements, herbal preparations, or alternative treatments, patients should speak with their oncology team because some products can interact with cancer medicines or affect bleeding and immune function.

Vaccination planning is also worth discussing with the care team. Certain lymphoma treatments can reduce immune responses, and live vaccines may not be suitable for some people. Emotional support is equally important: uncertainty during active monitoring can be difficult, and counseling, support groups, family support, or oncology social work services may help individuals manage practical and emotional concerns.

When to Seek Medical Care

Medical assessment is recommended for a lymph node that remains enlarged for several weeks, continues to grow, or is accompanied by persistent tiredness, recurrent fevers, drenching night sweats, unexplained weight loss, or a feeling of fullness in the upper abdomen. These symptoms are often caused by conditions other than lymphoma, but a clinician can determine whether examination and testing are needed.

People already diagnosed with marginal zone lymphoma should contact their care team promptly if they develop rapidly enlarging lymph nodes, new severe abdominal pain, increasing shortness of breath, significant bleeding, repeated infections, a marked decline in energy, or new symptoms that interfere with daily activities. These changes may need timely evaluation, even though they do not always indicate lymphoma progression.

Urgent medical care is appropriate for severe breathing difficulty, chest pain, fainting, uncontrolled bleeding, confusion, or severe abdominal pain. For non-urgent questions about monitoring, treatment effects, or symptoms between appointments, contacting the hematology or oncology team is the safest next step.

Frequently asked questions

Is marginal zone lymphoma curable?

Some localized marginal zone lymphomas, particularly certain MALT lymphomas treated with antibiotics or radiation therapy, can be controlled for a very long time and may not return. More widespread forms are often managed as chronic, slow-growing conditions. The outlook depends on the subtype, extent of disease, response to treatment, and individual health factors.

Is marginal zone lymphoma aggressive?

Marginal zone lymphoma is usually classified as an indolent or slow-growing lymphoma. It may remain stable for long periods, and some people do not need treatment immediately. Rarely, it can change into a faster-growing lymphoma, which is one reason regular follow-up is recommended.

Can Helicobacter pylori cause marginal zone lymphoma?

Chronic Helicobacter pylori infection is associated with many cases of MALT lymphoma in the stomach. Treating the infection with appropriate antibiotics can cause the lymphoma to regress in some people. Not every stomach MALT lymphoma is linked to this infection, so testing and follow-up are important.

How is marginal zone lymphoma different from other non-Hodgkin lymphomas?

Marginal zone lymphoma arises from mature B cells and typically grows more slowly than aggressive lymphomas such as diffuse large B-cell lymphoma. It also has characteristic subtypes involving mucosal tissues, lymph nodes, or the spleen. A biopsy and specialized laboratory testing are needed to identify the exact lymphoma type.

Will everyone with marginal zone lymphoma need chemotherapy?

No. Some people are monitored without immediate treatment, while others may receive antibiotics for stomach MALT lymphoma, radiation for localized disease, or antibody-based therapy. Chemotherapy may be considered when lymphoma is extensive, symptomatic, progressing, or affecting normal organ function or blood counts.

How often is follow-up needed after diagnosis?

Follow-up frequency varies according to whether a person is under active monitoring, receiving treatment, or in remission. Visits commonly include a symptom review, physical examination, and blood tests, with imaging used when clinically appropriate. The treating hematologist can provide an individualized surveillance schedule.

References

• American Cancer Society
• National Cancer Institute
• Leukemia & Lymphoma Society
• European Society for Medical Oncology
• World Health Organization

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.